E-viri
Recenzirano
Odprti dostop
-
Riabov, Vladimir; Xu, Qingyu; Schmitt, Nanni; Streuer, Alexander; Ge, Guo; Bolanos, Lyndsey; Wunderlich, Mark; Jann, Johann-Christoph; Wein, Alina; Altrock, Eva; Demmerle, Marie; Mukherjee, Sanjay; Ali, Abdullah Mahmood; Rapp, Felicitas; Nowak, Verena; Weimer, Nadine; Obländer, Julia; Palme, Iris; Göl, Melda; Jawhar, Ahmed; Darwich, Ali; Wuchter, Patrick; Weiss, Christel; Raza, Azra; Foulks, Jason M; Starczynowski, Daniel T; Yang, Feng-Chun; Metzgeroth, Georgia; Steiner, Laurenz; Jawhar, Mohamad; Hofmann, Wolf-Karsten; Nowak, Daniel
Haematologica (Roma), 05/2024, Letnik: 109, Številka: 5Journal Article
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor and indirect transcriptional repressor of the anti-apoptotic factor MCL-1, has previously shown clinical activity in AML. Availability of biomarkers for response to the alvocidib + 5-azacytidine (5-AZA) could also extend the rationale of this treatment concept to high-risk MDS. In this study, we performed a comprehensive in vitro assessment of alvocidib and 5-AZA effects in N=45 high-risk MDS patients. Our data revealed additive cytotoxic effects of the combination treatment. Mutational profiling of MDS samples identified ASXL1 mutations as predictors of response. Further, increased response rates were associated with higher gene expression of the pro-apoptotic factor NOXA in ASXL1-mutated samples. The higher sensitivity of ASXL1 mutant cells to the combination treatment was confirmed in vivo in ASXL1Y588X transgenic mice. Overall, our study demonstrated augmented activity for the alvocidib + 5-AZA combination in higher-risk MDS and identified ASXL1 mutations as a biomarker of response for potential stratification studies.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.